10,581 Shares in Solventum Co. (NYSE:SOLV) Purchased by Nicollet Investment Management Inc.

Nicollet Investment Management Inc. purchased a new position in Solventum Co. (NYSE:SOLVFree Report) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 10,581 shares of the company’s stock, valued at approximately $560,000.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in SOLV. Deseret Mutual Benefit Administrators purchased a new position in shares of Solventum during the second quarter valued at about $25,000. Partnership Wealth Management LLC purchased a new position in Solventum during the 2nd quarter valued at approximately $26,000. Richard W. Paul & Associates LLC purchased a new position in Solventum during the 2nd quarter valued at approximately $26,000. Family Firm Inc. bought a new stake in Solventum in the 2nd quarter worth approximately $26,000. Finally, M&R Capital Management Inc. purchased a new stake in shares of Solventum during the 2nd quarter worth approximately $27,000.

Solventum Price Performance

Solventum stock opened at $68.35 on Wednesday. The company has a debt-to-equity ratio of 2.90, a quick ratio of 0.96 and a current ratio of 1.31. Solventum Co. has a 1-year low of $47.16 and a 1-year high of $96.05. The stock has a 50-day moving average price of $57.59.

Solventum (NYSE:SOLVGet Free Report) last issued its quarterly earnings results on Thursday, August 8th. The company reported $1.56 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.46 by $0.10. The business had revenue of $2.08 billion for the quarter, compared to the consensus estimate of $2.05 billion. Solventum’s quarterly revenue was up .2% on a year-over-year basis. On average, equities research analysts anticipate that Solventum Co. will post 6.38 EPS for the current year.

Wall Street Analyst Weigh In

SOLV has been the topic of several research reports. Morgan Stanley reduced their price target on shares of Solventum from $70.00 to $55.00 and set an “equal weight” rating on the stock in a research report on Monday, July 15th. The Goldman Sachs Group boosted their target price on shares of Solventum from $48.00 to $54.00 and gave the stock a “sell” rating in a report on Monday, August 12th. Argus assumed coverage on shares of Solventum in a report on Monday, June 24th. They issued a “hold” rating for the company. Bank of America reduced their price objective on Solventum from $70.00 to $60.00 and set a “neutral” rating on the stock in a research note on Tuesday, June 25th. Finally, Wells Fargo & Company lowered their price objective on Solventum from $69.00 to $64.00 and set an “equal weight” rating for the company in a research note on Friday, August 9th. One research analyst has rated the stock with a sell rating and six have given a hold rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $58.25.

Read Our Latest Research Report on Solventum

About Solventum

(Free Report)

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.

Featured Stories

Want to see what other hedge funds are holding SOLV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Solventum Co. (NYSE:SOLVFree Report).

Institutional Ownership by Quarter for Solventum (NYSE:SOLV)

Receive News & Ratings for Solventum Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solventum and related companies with MarketBeat.com's FREE daily email newsletter.